Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: A PCCTC trial

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 3, 2012, Pages 763-771

  Antonarakis, Emmanuel S ^a   Carducci, Michael A ^a   Eisenberger, Mario A ^a   Denmeade, Samuel R ^a   Slovin, Susan F ^b   Jelaca Maxwell, Kathy ^c   Vincent, Martha E ^c   Scher, Howard I ^b   Morris, Michael J ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c Agensys Inc   (United States)

Author keywords

AGS 1C4D4; Castration resistant prostate cancer; Monoclonal antibody; Phase I; PSCA

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY AGS-1C4D4; PROSTATE STEM CELL ANTIGEN; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; AGED; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG FATALITY; DRUG FEVER; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HUMAN; IMMUNOGENICITY; MALE; MAXIMUM PLASMA CONCENTRATION; METASTASIS; MUSCULOSKELETAL PAIN; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SINGLE DRUG DOSE; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; GPI-LINKED PROTEINS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 84859475889     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1759-9     Document Type: Article

References (14)

1. Jakobovits A (2008) Monoclonal antibody therapy for prostate cancer. Handb Exp Pharmacol 181:237-256
2. Reiter RE, Gu Z, Watabe T et al (1998) Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci USA 95:1735-1740 (Pubitemid 28103463)
3. Gu Z, Thomas G, Yamashiro J et al (2000) Prostate stem cell antigen (PSCA) expression increases with high Gleason score, advanced stage and bone metastases in prostate cancer. Oncogene 19:1288-1296 (Pubitemid 30160621)
4. Han KR, Seligson DB, Liu X et al (2004) Prostate stem cell antigen expression is associated with Gleason score, seminal vesicle invasion and capsular penetration in prostate cancer. J Urol 171:1117-1121 (Pubitemid 38327539)
5. Lam JS, Yamashiro J, Shintaku IP et al (2005) Prostate stem cell antigen is overexpressed in prostate cancer metastases. Clin Cancer Res 11:2591-2596 (Pubitemid 40569458)
6. Saffran DC, Raitano AB, Hubert RS et al (2001) Anti-PSCA monoclonal antibodies inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts. Proc Natl Acad Sci USA 98:2658-2663 (Pubitemid 32209538)
7. Jakobovits A, Gudas JM, Jia X et al (2005) Therapeutic potential of AGS-PSCA: a fully human monoclonal antibody to prostate stem cell antigen (PSCA) for the treatment of prostate and pancreatic cancers. J Clin Oncol 23(Suppl): abstract 4722
8. Morris MJ, Eisenberger MA, Pili R et al (2009) Phase Ib study of AGS-PSCA, an anti-PSCA human antibody, in castration-resistant prostate cancer. Genitourinary Cancers Symposium: abstract 174
9. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216 (Pubitemid 30099779)
10. Pound CR, Partin AW, Eisenberger MA et al (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281:1591-1597 (Pubitemid 29211767)
11. D'Amico AV, Chen MH, Roehl KA et al (2004) Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351:125-135
12. Gu Z, Yamashiro J, Kono E et al (2005) Anti-prostate stem cell antigen monoclonal antibody 1G8 induces cell death in vitro and inhibits tumor growth in vivo via a Fc-independent mechanism. Cancer Res 65:9495-9500 (Pubitemid 41508019)
13. Amara N, Palapattu GS, Schrage M et al (2001) Prostate stem cell antigen is overexpressed in human transitional cell carcinoma. Cancer Res 61:4660-4665 (Pubitemid 32691871)
14. Argani P, Rosty C, Reiter RE et al (2001) Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma. Cancer Res 61:4320-4324 (Pubitemid 32685751)